

ASX Release

Distribution Of Security Holders

PERTH, AUSTRALIA – 5 August 2020: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oromucosal drug delivery, is pleased to announce, in addition to the top 20 security holders, the distribution of security holders as outlined below.

Shareholders

<u>SPREADS OF HOLDINGS</u>	<u>NUMBER OF HOLDERS</u>	<u>NUMBER OF UNITS</u>	<u>% OF TOTAL ISSUED CAPITAL</u>
1 - 1,000	682	320,154	0.11%
1,001 - 5,000	751	2,047,173	0.72%
5,001 - 10,000	510	3,818,568	1.34%
10,001 - 100,000	1,180	42,702,899	15.01%
100,001 - 999,999,999,999	444	235,620,000	82.82%
TOTAL	3,567	284,508,794	100%

<u>LOCALITY ANALYSIS</u>	<u>NUMBER OF HOLDERS</u>	<u>NUMBER OF UNITS</u>	<u>% OF TOTAL ISSUED CAPITAL</u>
WESTERN AUSTRALIA	915	84,427,099	29.68%
VICTORIA	913	60,853,222	21.39%
NEW SOUTH WALES	876	76,344,822	26.83%
QUEENSLAND	488	32,702,246	11.49%
SOUTH AUSTRALIA	172	6,709,604	2.36%
AUSTRALIAN CAPITAL TERRITORY	68	14,436,205	5.07%
TASMANIA	49	2,058,206	0.72%
NORTHERN TERRITORY	31	5,802,290	2.04%
NEW ZEALAND	43	1,047,095	0.37%
REPUBLIC OF SINGAPORE	3	6,200	0.00%
UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND	3	1,626	0.00%
HONG KONG	2	113,333	0.04%
THAILAND	1	5,613	0.00%
REPUBLIC OF INDIA	1	300	0.00%
REPUBLIC OF BOTSWANA	1	533	0.00%
MALAYSIA	1	400	0.00%
Total Australian Holders	3,512	283,333,694	99.59%
Total Overseas Holders	55	1,175,100	0.41%
Grand Total	3,567	284,508,794	100.00%

Option holders (SU DOE)

<u>SPREADS OF HOLDINGS</u>	<u>NUMBER OF HOLDERS</u>	<u>NUMBER OF UNITS</u>	<u>% OF TOTAL ISSUED CAPITAL</u>
1 - 1,000	59	24,463	0.05%
1,001 - 5,000	172	491,286	1.04%
5,001 - 10,000	87	643,819	1.36%
10,001 - 100,000	276	9,553,518	20.15%
100,001 - 999,999,999,999	109	36,705,292	77.41%
TOTAL	703	47,418,378	100%

<u>LOCALITY ANALYSIS</u>	<u>NUMBER OF HOLDERS</u>	<u>NUMBER OF UNITS</u>	<u>% OF TOTAL ISSUED CAPITAL</u>
WESTERN AUSTRALIA	195	15,988,715	33.72%
VICTORIA	176	8,219,067	17.33%
NEW SOUTH WALES	160	11,871,544	25.04%
QUEENSLAND	97	6,144,320	12.96%
SOUTH AUSTRALIA	30	998,416	2.11%
AUSTRALIAN CAPITAL TERRITORY	23	2,897,792	6.11%
TASMANIA	9	308,135	0.65%
NORTHERN TERRITORY	8	900,877	1.90%
NEW ZEALAND	5	89,512	0.19%
Total Australian Holders	698	47,328,866	99.81%
Total Overseas Holders	5	89,512	0.19%
Grand Total	703	47,418,378	100.00%

Option holders (SUDOD)

<u>SPREADS OF HOLDINGS</u>	<u>NUMBER OF HOLDERS</u>	<u>NUMBER OF UNITS</u>	<u>% OF TOTAL ISSUED CAPITAL</u>
1 - 1,000	214	105,698	0.51%
1,001 - 5,000	171	443,626	2.14%
5,001 - 10,000	96	736,541	3.56%
10,001 - 100,000	171	5,983,542	28.92%
100,001 - 999,999,999,999	39	13,418,644	64.86%
TOTAL	691	20,688,051	100%

<u>LOCALITY ANALYSIS</u>	<u>NUMBER OF HOLDERS</u>	<u>NUMBER OF UNITS</u>	<u>% OF TOTAL ISSUED CAPITAL</u>
WESTERN AUSTRALIA	172	6,011,768	29.06%
NEW SOUTH WALES	169	6,430,416	31.08%
VICTORIA	165	5,091,793	24.61%
QUEENSLAND	96	1,811,378	8.76%
SOUTH AUSTRALIA	45	297,275	1.44%
AUSTRALIAN CAPITAL TERRITORY	17	367,736	1.78%
TASMANIA	10	210,187	1.02%
NORTHERN TERRITORY	9	300,325	1.45%
NEW ZEALAND	7	67,173	0.33%
UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND	1	100,000	0.48%
Total Australian Holders	683	20,520,878	99.19%
Total Overseas Holders	8	167,173	0.81%
Grand Total	691	20,688,051	100.00%

For and on behalf of the Board and for further information please contact:

Paul Hopper
Chairman
SUDA Pharmaceuticals Ltd
Tel: +61 (0) 406 671 515
phopper@sudapharma.com

Dr Michael Baker
Chief Executive Officer & Managing Director
SUDA Pharmaceuticals Ltd
Tel +61 (0) 403 468 187
mbaker@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of: migraine headache; chemotherapy-induced nausea and vomiting; erectile dysfunction; pulmonary hypertension; epileptic seizures and pre-procedural anxiety and cancer.

For more information, visit www.sudapharma.com